Editorial Perspectives On Patient Recruitment

  1. Clinical Trials In APAC: Challenges And Opportunities 9/29/2022

    For several years, the APAC region has been one of the hottest growth regions for clinical trials. In June 2022, I had the opportunity to sit down with three experts on the region. They were able to discuss the growth of trials in the APAC region, the opportunities presented to sponsor companies, and the challenges that still exist.

  2. Walgreens Is Ready To Re-Envision Recruitment, DCTs, And RWE 9/12/2022

    Since becoming CEO of Walgreens Boots Alliance (WBA) in March 2021, Rosalind Brewer has been focused on healthcare and what the company could do to help its patients. WBA refers to the integrated healthcare, pharmacy, and retail store that currently serves millions of customers and patients every day. This past June, the company launched its clinical trial business. 

  3. LLS is Working To Change The Pediatric Clinical Trial Model 8/11/2022

    In pediatric trials, answers do not come quickly. The trials are time consuming, and many sites are required. That means costly studies and an end market that is small. This leads pharma companies to adopt a business model that focuses on an indication that will help the most people. But that model also means children will always be at the end of the line.

  4. Novartis Lights A Beacon Of Hope For Diversity And Inclusion 7/21/2022

    In June 2022 Novartis announced the expansion of its Beacon of Hope program. The program is a 10-year, multimillion dollar program being conducted in collaboration with 26 historically Black colleges, universities, medical schools, Thurgood Marshall College Fund (TMCF) and other key partners.

  5. SCRS Puts A Spotlight On Diversity 6/9/2022

    When asked about patient diversity in clinical trials, Diana Foster likes to reflect back to 2016. Foster, VP, strategy and special projects & diversity awareness program lead at the Society for Clinical Research Sites (SCRS), notes that was the year a group of individuals from approximately 40 organizations gathered in Washington D.C. to discuss diversity.

  6. AstraZeneca's Oncology Goal: Separate Efficacy And Toxicity 6/6/2022

    Matthew Ellis, SVP of Early Oncology R&D for AstraZeneca, is helping lead the charge in what he calls the company's oncology revolution. Ellis deals with the complicated process of going from the discovery of a potential therapeutic target or mechanism to the discovery and development of potential medicines, the triage of those medicines, and working out the right risk-benefit profile so they can be administered to humans.

  7. Developing A Plan For Patient Diversity? The FDA Shares Advice 4/25/2022

    The FDA has released a draft guidance discussing patient diversity. The guidance recommends that sponsor companies include a plan to increase diversity in the clinical trial designs they propose to the agency.

  8. Report Reflects Huge Growth of Clinical Trials In China 12/14/2021

    China has been a hot topic in the clinical space for several years, and companies locating clinical trials in the APAC region is now a trending topic in the life sciences. A new report from Global Data shows the degree to which China has been attracting studies.

  9. One Year In, DTRA Meets Goals & Looks To The Future 12/1/2021

    In November 2021, the Decentralized Trial & Research Alliance (DTRA) held its annual meeting in Boston. The DTRA was formed in 2020 with more than 70 founding members from pharma companies and their technology and service partners. I took this opportunity to speak with Craig Lipset, DTRA’s co-chair, about the progress the organization has made and its vision for the future.

  10. A Lesson Learned From Big Pharma: Don't Be Afraid To Go Global 11/19/2021

    The rheumatic diseases Kezar Life Sciences is attempting to treat have racial disparities across the world that create different outcomes and incidence rates of autoimmune disorders. Those considerations must come into play when thinking about trial design. The company has learned you should not be afraid to go global as early as possible.